KRAS

KRAS is an oncogene that encodes a signaling protein involved in cell growth and division. KRAS mutations are among the most common drivers of cancer, historically considered "undruggable" until recent breakthrough therapies, making it a critical biomarker for treatment selection.

Why KRAS Is Being Studied for Cancer

  • Drives uncontrolled cell proliferation when mutated

  • Present in approximately 25% of all human cancers

  • Different KRAS mutations (G12C, G12D, G12V) have distinct implications

  • Recently became targetable with new approved drugs

  • Affects response to EGFR-targeted therapiesCancer Types Being Studied

    Cancer Types Where KRAS Is Significant

    • Pancreatic cancer (90% mutation rate)

    • Colorectal cancer (40-50%)

    • Non-small cell lung cancer (25-30%)

    • Endometrial cancer

    • Ovarian cancer

    • Cholangiocarcinoma

Common Research Questions

  • Should all cancer patients be tested for KRAS mutations?

  • Which KRAS mutations are now targetable?

  • How does KRAS status affect treatment options?

  • What does KRAS mutation mean for prognosis?

Related Topics in Our Archive

  • KRAS G12C inhibitor

  • KRAS mutation cancer

  • KRAS and EGFR therapy

  • Sotorasib KRAS

  • Adagrasib KRAS

What Researchers Are Studying

  • Inhibitors for non-G12C KRAS mutations

  • Combination therapies to prevent resistance

  • KRAS as predictor of immunotherapy response

  • Mechanisms of resistance to KRAS inhibitors

Browse KRAS Research

→ Search our archive for "KRAS"

Disclaimer

This page is for informational purposes only. Always consult your oncologist before adding any supplement to your treatment plan.